Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Viral vectors for malaria vaccine development.
Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F. Li S, et al. Among authors: monath tp. Vaccine. 2007 Mar 30;25(14):2567-74. doi: 10.1016/j.vaccine.2006.07.035. Epub 2006 Aug 1. Vaccine. 2007. PMID: 16914237 Free PMC article. Review.
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.
Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, Excler JL, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Monath TP, et al. Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Vaccine. 2015. PMID: 25446819 Free PMC article. Review.
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.
Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Monath TP, et al. Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11. Vaccine X. 2019. PMID: 31384731 Free PMC article.
Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.
Penaloza MacMaster P, Shields JL, Alayo QA, Cabral C, Jimenez J, Mondesir J, Chandrashekar A, Cabral JM, Lim M, Iampietro MJ, Provine NM, Bricault CA, Seaman M, Orlinger K, Aspoeck A, Fuhrmann G, Lilja AE, Monath T, Mangeat B, Pinschewer DD, Barouch DH. Penaloza MacMaster P, et al. Vaccine. 2017 Jan 3;35(1):1-9. doi: 10.1016/j.vaccine.2016.11.063. Epub 2016 Nov 26. Vaccine. 2017. PMID: 27899229 Free PMC article.
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.
Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, Gurwith M, Bok K, Robertson JS, Kim D, Michael Hendry R, Singh V, Mac LM, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Condit RC, et al. Among authors: monath tp. Vaccine. 2016 Dec 12;34(51):6610-6616. doi: 10.1016/j.vaccine.2016.04.060. Epub 2016 Jun 23. Vaccine. 2016. PMID: 27346303 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Condit RC, Kim D, Robertson JS, Excler JL, Gurwith M, Monath TP, Pavlakis G, Fast PE, Smith J, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO) Working Group. Electronic address: bc-coordinator@taskforce.org. Condit RC, et al. Among authors: monath tp. Vaccine. 2020 Nov 17;38(49):7708-7715. doi: 10.1016/j.vaccine.2020.08.009. Epub 2020 Sep 6. Vaccine. 2020. PMID: 32907759 Free PMC article. Review.
332 results